Morphogen treatments for limiting proliferation of epithelial cells
View Patent ↗Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.
1. A method for limiting the mitogenic activity of proliferating epithelial cells in a mammal in need thereof, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with said epithelial cells, wherein said morphogen:
(i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38–139 of SEQ ID NO: 5;
(ii) is not TGFβ2; and
(iii) is capable of inhibiting lesion formation in an in vivo oral mucositis assay, so as to thereby limit the mitogenic activity of said cells in said mammal.
2. The method of claim 1 , wherein said epithelial cells are epidermal skin cells.
3. The method of claim 2 , wherein proliferation of said cells is associated with psoriasis.
4. A method for inhibiting scar tissue formation at a site of tissue damage in a mammal, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with cells at a site of tissue damage in the mammal, wherein said morphogen:
(i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38–139 of SEQ ID NO: 5;
(ii) is not TGFβ2; and
(iii) is capable of inhibiting lesion formation in an in vivo oral mucositis assay, so as to thereby inhibit scar tissue formation at a site of tissue damage in said mammal.